Treatment of sepsis: past and future avenues
Details
Serval ID
serval:BIB_E2CF03AE23AB
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Treatment of sepsis: past and future avenues
Journal
Drugs
ISSN
0012-6667
Publication state
Published
Issued date
02/1999
Peer-reviewed
Oui
Volume
57
Number
2
Pages
127-32
Notes
Journal Article
Research Support, Non-U.S. Gov't
Review --- Old month value: Feb
Research Support, Non-U.S. Gov't
Review --- Old month value: Feb
Abstract
In recent years, the concept has emerged that the host's inflammatory response contributes substantially to the development of septic shock and organ failure. Experimental observations prompted large scale randomised clinical trials with a variety of agents such as glucocorticoids, ibuprofen, antiendotoxin monoclonal antibodies, antagonists of platelet-activating factor, of bradykinin or of interleukin-1 receptor, and monoclonal anti-tumour necrosis factor (TNF) antibodies or soluble dimeric TNF receptor fusion proteins. All these major studies of immunomodulators in sepsis have yielded disappointing results despite showing promise during preliminary clinical studies. However, these recent failures do not mean that septic shock will forever remain an insurmountable medical challenge. Many lessons have been learned from these studies. and certain mistakes in their study design will be avoided in the future. Our understanding of the pathophysiology of sepsis and septic shock is increasing markedly; potential new treatment strategies are available and could be explored to improve the outcome of patients with sepsis.
Keywords
Animals
Forecasting
Humans
Sepsis/*drug therapy/*prevention & control
Shock, Septic/*drug therapy/prevention & control
Pubmed
Web of science
Create date
19/01/2008 19:12
Last modification date
20/08/2019 17:06